Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095631 | 0.90 | CSNK2A1 (0.43) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| Hydrochloric Acid SCHEMBL6097166 | 0.89 | CSNK2A1 (0.42) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4793038 | 0.84 | CSNK2A1 (0.38) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL6680893 | 0.83 | TLR7 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4790972 | 0.82 | CSNK2A1 (0.38) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4794033 | 0.82 | CSNK2A1 (0.38) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4792194 | 0.82 | TLR8 (0.43) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL4791595 | 0.81 | CSNK2A1 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| SCHEMBL5339643 | 0.81 | CSNK2A1 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 | |
| Hydrochloric Acid SCHEMBL6820241 | 0.81 | CSNK2A1 (0.37) | CSNK2A1PIM1CSNK2A2CSNK2BCSNK2A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6720333-B2 | IMMUNE RESPONSE MODIFIERS; CYTOKINE BIOSYNTHESIS; VIRAL AND NEOPLASTIC DISEASES; N-(4-(4-AMINO-6,7-DIMETHYL-1H-IMIDAZO (4,5-C)PYRIDIN-1-YL)BUTYL)BENZAMIDE | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-13 | — | — | US | claimed |
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1542688-A2 | 1H-IMIDAZO DIMERS | 3M Innovative Properties Company (US) | 2005-06-22 | — | — | EP | disclosed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1451187-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003050119-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050118-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | CSNK2A1 1438/4885PIM1 197/4885CSNK2A2 1695/4885 |
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | CSNK2A1 3094/4885PIM1 396/4885CSNK2A2 3323/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | CSNK2A1 3094/4885PIM1 396/4885CSNK2A2 3323/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | CSNK2A1 1438/4885PIM1 197/4885CSNK2A2 1695/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | CSNK2A1 1438/4885PIM1 197/4885CSNK2A2 1695/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | CSNK2A1 1438/4885PIM1 197/4885CSNK2A2 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.